Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMZVFOQ)

Drug Name

GS-5829 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 1	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Bromodomain and extraterminal domain protein (BET)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
CPI-0610	DMPXOYJ	Myelofibrosis	2A20.2	Phase 3	[1]
ZEN-3694	DM6VQTF	Prostate cancer	2C82.0	Phase 2	[2]
OTX-015	DMI8RG1	Acute myeloid leukaemia	2A60	Phase 1/2	[1]
BMS-986158	DM6LDI4	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[1]
INCB054329	DM7TZL0	Refractory hematologic malignancy	2A85.5	Phase 1/2	[3]
INCB057643	DMG65CV	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[4]
ODM-207	DMOKVJD	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[5]
(+)-JQ1	DM1CZSJ	Testicular cancer	2C80	Phase 1	[6]
GSK525762	DMPAWBN	Haematological malignancy	2B33.Y	Phase 1	[1]
PLX51107	DMXLHVW	Haematological malignancy	2B33.Y	Phase 1	[1]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Bromodomain and extraterminal domain protein (BET)	TTE4BSY	NOUNIPROTAC	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2	Clinical pipeline report, company report or official report of Zenith Epigenetics.
3	The Novel Bromodomain and Extraterminal Domain Inhibitor INCB054329 Induces Vulnerabilities in Myeloma Cells That Inform Rational Combination Strategies. Clin Cancer Res. 2019 Jan 1;25(1):300-311.
4	Development of 2 Bromodomain and Extraterminal Inhibitors With Distinct Pharmacokinetic and Pharmacodynamic Profiles for the Treatment of Advanced Malignancies. Clin Cancer Res. 2020 Mar 15;26(6):1247-1257.
5	First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours. Br J Cancer. 2020 Dec;123(12):1730-1736.
6	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)